Clinical Trials Browser

Phase 2 × anagrelide × Myeloid × Clear all

NCT03123588 2021-11-19

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Phase 2 Terminated

12 enrolled 15 charts

Myeloproliferative Disorders, Thrombocythemia, Essential